All posts related to "medication"

Research shows arthritis medication may slow Alzheimer’s

Brain xrayA recent research from the University of Southampton shows that the arthritis medication, etanarcept (Enbrel®), may slow Alzheimer’s disease. The research was presented at the Alzheimer’s Association International Conference in Denmark last week.

In the small control study, a group of 41 patients exhibiting mild or moderate Alzheimer’s was given either the anti-inflammatory medication etanercept or a placebo every week over a period of six months.

Researchers monitored memory function in patients and found that the efficiency of day-to-day activities and behaviour and the symptoms of those who had taken etanercept did not get any worse. In comparison, the placebo group showed signs of decline in memory function.

In an interview with the Daily Mail, lead researcher, Professor Clive Holmes, said:

Continue reading

AS it Goes – Too Good to be True?

Symbol of a target with and arrow and the word "promo"

Photo courtesy of Stuart Miles with FreeDigitalPhotos.net

Last week, my computer mouse inadvertently hovered over some advertising scrolling along the screen and I was instantly transported to another website.

This is not the first time this has happened, but before I became involved in an investment pitch or a cure for belly fat (both of which I probably could use), I warned myself to be remain vigilant and then repeatedly hit the “back” button until I was safely back on the terra firma of my home page. Continue reading

Innovation in Action

magnifying glass

Innovation in Action: Annual arthritis conference brings experts from around the globe to share research, improve patient care

The American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) meet once a year, bringing researchers from around the world together so they may share information and discuss the latest science, research, and treatments in the field of rheumatology. Innovative sessions, groundbreaking science, education that fills knowledge and practice gaps, and hands-on skills training make up some of the activities of the event.

The goals of the annual conference include:

  • Identifying developments in disease diagnosis and treatments.
  • Describing potential issues in delivery of care and sharing ideas for solutions.
  • Summarizing recent research findings.
  • Using new research data to improve the quality of patient care.
  • Encouraging research that leads to new treatment protocols.

Arthritis Consumer Experts was at the most recent event, held in October 2013, to represent people living with arthritis and to learn about the latest research findings so we could share them with you. Of particular interest to consumers were two presentations: One was about the current state of osteoarthritis treatment and ways to improve outcomes in the future. The other discussed recent advances in psoriatic arthritis research and how they could be used to effectively identify, diagnose, and treat the disease to improve patients’ quality of life and function. Continue reading

Patient forum coming soon

The Spondyloarthritis Research Consortium of Canada (SPARCC) and the Canadian Spondylitis Association (CSA) are pleased to announce an upcoming patient forum on ankylosing spondylitis (AS).

Patients with AS and a family member are invited to attend this free informational event. Lectures and activities include:

  • Current concepts on the cause of AS.
  • Update on the medical treatment of AS.
  • Information non-pharmacologic treatment of AS.
  • Ask the experts.

Contact Maria Morales at mmorales@uhnresearch.ca or call 416-603-5800, or complete the registration form, which can be found below. The registration form is also available at www.sparccc.ca and www.spondylitis.ca.

2014 Ankylosing Spondylitis Patient Forum

Accelerating Medicines Partnership promotes teamwork in pharmaceutical industry

Stick Man holding handsTen big drug companies have joined together with the National Institutes of Health (NIH) to accelerate the discovery of new medicines for diseases like alzheimers, diabetes, rheumatoid arthritis and lupus. The project is called the Accelerating Medicines Partnership. Under the five-year agreement, the companies will be sharing scientists, tissue and blood samples, and data. The underlying goal is to help identify targets for new drugs. Continue reading

Good news for Yukon residents

Yukon flag clip artCriteria for denosumab (Prolia®) for osteoporosis and tocilizumab (Actemra®) for rheumatoid arthritis updated.

The Yukon recently added two medications to its Drug Formulary: denosumab (Prolia®) for osteoporosis and tocilizumab (Actemra®) for rheumatoid arthritis. Both medications are considered an Exception drug under the Pharmacare (seniors plan) and the Chronic Disease Program, which requires an application for the Formulary Working Group to assess. Continue reading